Some Common Protocols |
Breast cancer |
v FAC: fluorouracil + doxorubicin + and cyclophosphamide |
v CMF: cyclophosphamide + methotrexate + fluorouracil |
v FEC: fluorouracil + epirubicin + cyclophosphamide |
v AC: doxorubicin + cyclophosphamide |
v TC: docetaxel + cyclophosphamide |
v TA: docetaxel + Adriamycin |
v TCH: docetaxel + cyclophosphamide + HERCEPTIN® |
v PH: paclitaxel + HERCEPTIN® |
v AC →TH (Adriamycin + cyclophosphamide) then TAXOTER® + HERCEPTIN® |
Lung cancer |
v Platinum compounds, taxanes, gemcitabine, & etoposide are used. |
v CP: cisplatin + paclitaxel |
v GC: gemcitabine + cisplatin |
v DC: docetaxel + cisplatin |
v PCb: paclitaxel + carboplatin |
v EC: etoposide + cisplatin |
Colorectal cancer |
v FOLFOX or FLOX: fluorouracil + leucovorin + oxaliplatin |
v FOLFIRI: fluorouracil + leucovorin + irinotecan |
v IROX: irinotecan + oxaliplatin |
v CapOX: capecitabine + oxaliplatin |
v XELOX: XELODA® (capecitabine) + oxaliplatin |
v Bevacizumab, cetuximab, or panitumumab can be added to previous protocols. |
Brain tumors |
v Carmustine (BCNU), lomustine (CCNU), temozolamide, procarbazine, & bevacizumab. |
v PCV: procarbazine, CCNU, & vincristine. |
Acute lymphoblastic leukemia (ALL) |
v Acute lymphoblastic leukemia (ALL) is the main form of leukemia in childhood, and it is the most common form of cancer in children. |
Agents active against this form: |
v Methotrexate, corticosteroids, 6-mercaptopurine, cyclophosphamide, vincristine, daunorubicin, and asparaginase. |
Adult Leukemia |
v Acute myelogenous leukemia (AML) is the most common leukemia in adults. |
v Cytarabine + anthracyclines (idarubicin) → remission in about 70% of cases. |
Chronic myelogenous leukemia (CML) |
v Arises from a chromosomally abnormal hematopoietic stem cell in which a balanced translocation between the long arms of chromosomes 9 and 2. |
v BCR-ABL tyrosine kinase inhibitors: imatinib, nilotinib, & dasatinib are effective. |
v Other alkylating agents, hydroxy urea, & interferon alpha can be used. |
Chronic lymphocytic leukemia (CLL) |
v Chlorambucil and cyclophosphamide are the two most widely used alkylating agents for this disease. |
v COP: Cyclophosphamide + vincristine (oncovine) + prednisone. |
v CHOP: as the previous + doxorubicin. |
v Rituximab: anti CD-20 MAB. |
Hodgkin’s lymphoma |
v MOPP: mechlorethamine + vincristine (oncovin) + procarbazine + prednisone. |
v ABVD: Adriamycin (doxorubicin) + bleomycin + vinblastine + dacarbazine. |
Non-Hodgkin’s lymphoma |
v CHOP: cyclophosphamide + doxorubicin + vincristine (oncovin) + prednisone. |
v Rituximab may be added to the previous regimen. |
Multiple myeloma (MM) |
v MP: melphalan + prednisone |
v VAD: vincristine + doxorubicin + dexamethasone |
v Lenalidomide & bortezomib are used in MM. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|